ARTICLE | Company News
Immune Response autoimmune news
April 9, 2007 7:00 AM UTC
IMRP will restructure and reduce headcount by 17 in its King of Prussia, Penn., manufacturing facility, bringing the company’s total headcount to 22. The reduction coincides with IMRP’s decision to seek strategic alternatives for its HIV program including IR103, which did not show a reduction in viral load vs. placebo in a Phase II trial in February (see BioCentury, Feb. 19). ...